Lineage-Specific Smooth Muscle Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving Smooth Muscle Cells (SMCs) from human pluripotent stem cells do not accurately recapitulate the lineage-restricted origins of SMCs, leading to inadequate models for disease modeling and regenerative medicine.
Innovation Solution
A method involving the use of lineage-specific induction media to differentiate pluripotent stem cells into specific embryonic lineage SMCs, including neuroectodermal and mesodermal SMCs, by culturing them in chemically defined media with specific growth factors and signaling pathway activators/inhibitors to produce progenitor cells and eventually SMCs of defined embryonic lineages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current methods for deriving SMCs from human PSCs are used, then SMC production is achieved, but the lineage-restricted origins of SMCs are not accurately recapitulated
Solution Approach 1:
The patent segments the differentiation process into distinct stages corresponding to specific embryonic lineages. By dividing the PSC population into neuroectodermal and mesodermal progenitor pathways through targeted induction media, the method recreates the natural lineage restriction that occurs during embryonic development, thereby improving manufacturing precision of lineage-specific SMCs.
Solution Approach 2:
The patent applies local quality by providing different lineage induction media with specific growth factors and signaling pathway activators tailored to each embryonic lineage. Neuroectodermal progenitors receive one composition while mesodermal progenitors receive another, ensuring that each cell population receives the appropriate local chemical environment to maintain its lineage identity and improve disease modeling accuracy.
2Manufacturing precision
If lineage-specific induction media are used to differentiate PSCs into specific embryonic lineage SMCs, then manufacturing precision is improved, but process complexity increases
Solution Approach 1:
The complex differentiation protocol is segmented into modular stages: PSC maintenance, lineage specification (neuroectodermal or mesodermal), and SMC differentiation. Each stage uses a defined induction medium with specific growth factors, allowing the complex process to be managed as discrete, reproducible steps rather than a monolithic procedure.
Solution Approach 2:
The patent controls lineage specification by changing key parameters in the induction media, such as the presence or absence of specific growth factors (e.g., BMP4, FGF2, TGF-beta) and signaling pathway modulators. By systematically varying these chemical parameters, the method directs PSCs toward specific lineages without requiring complex physical or biological manipulations.
Data Source
AI summary
This invention relates to the production of populations of Smooth Muscle Cells (SMCs) of specific embryonic lineages, such as neuroectodermal and mesodermal SMCs. Pluripotent stem cells are cultured in one or more lineage induction media to produce progenitor cells of a defined embryonic lineage, which are then cultured in an SMC induction medium to produce a population of SMCs of the embryonic lineage. Populations of SMCs of defined lineages may be useful, for example, in accurately modelling vascular disease.